Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
AKT1 positive Perifosine ovarian clear cell carcinoma predicted - sensitive detail...
AKT1 positive Cisplatin + Perifosine ovarian clear cell carcinoma predicted - sensitive detail...
Unknown unknown GDC-0980 ovarian clear cell carcinoma not applicable detail...
ARID1A mutant Dasatinib ovarian clear cell carcinoma sensitive detail...
TP53 del thioureidobutyronitrile ovarian clear cell carcinoma predicted - sensitive detail...
ARID1A mutant VE-821 ovarian clear cell carcinoma sensitive detail...
ARID1A mutant VX-970 ovarian clear cell carcinoma sensitive detail...
ARID1A loss JQ1 ovarian clear cell carcinoma predicted - sensitive detail...
ARID1A dec exp GSK525762 ovarian clear cell carcinoma predicted - sensitive detail...
ARID1A Q1148* JQ1 ovarian clear cell carcinoma predicted - sensitive detail...
Unknown unknown ENMD-2076 ovarian clear cell carcinoma no benefit detail...
ARID1A negative ENMD-2076 ovarian clear cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Recruiting
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Active, not recruiting
NCT03348631 Phase II Tazemetostat Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Recruiting
NCT03355976 Phase II Ipilimumab + Nivolumab Nivolumab BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting
NCT03602586 Phase II Epacadostat + Pembrolizumab Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma Suspended
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Recruiting
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Recruiting